Get the Stockscreener App
113.76
0.82%
0.92
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $113.76, with a volume of 954.55K.
It is up +0.82% in the last 24 hours and up +13.32% over the past month.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
See More
Previous Close:
$112.84
Open:
$113.37
24h Volume:
954.55K
Relative Volume:
0.69
Market Cap:
$12.69B
Revenue:
$2.90B
Net Income/Loss:
$239.11M
P/E Ratio:
53.92
EPS:
2.1097
Net Cash Flow:
$492.62M
1W Performance:
+0.20%
1M Performance:
+13.32%
6M Performance:
+15.90%
1Y Performance:
+12.75%
1-Day Range:
$112.19
$114.50
1-Week Range:
$109.62
$116.16
52-Week Range:
$81.22
$118.30
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, NTRA, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
113.76 | 12.41B | 2.90B | 239.11M | 492.62M | 2.1097 |
TMO
Thermo Fisher Scientific Inc
|
523.44 | 186.32B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
197.93 | 134.82B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.80 | 41.53B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
279.32 | 38.88B | 2.50B | -226.32M | 71.51M | -1.6412 |
WAT
Waters Corp
|
379.29 | 36.82B | 3.77B | 449.25M | 240.68M | 7.8556 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-25 | Initiated | Goldman | Neutral |
| Oct-16-25 | Initiated | Guggenheim | Neutral |
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Revvity Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Revvity, Inc. Expands Signals AI Ecosystem Through Anthropic Claude Integration - marketscreener.com
Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration - 01net
Revvity (RVTY) Enhances R&D Access through Partnership with Anth - GuruFocus
Revvity adds Signals connector to Anthropic’s Claude platform - Investing.com
Revvity adds Signals connector to Anthropic’s Claude platform By Investing.com - Investing.com Australia
Revvity lets scientists tap R&D data in Claude through new connector - Stock Titan
The EnLite Neonatal TREC kit from Revvity Inc.newborn screening focuses on severe immune defects - AD HOC NEWS
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
Revvity Q1 2026 Earnings: EPS Beats Estimates by 2.27% Amid Revenue DisclosuresEarnings Season Outlook - dars.gov.et
Signals AI boosts scientific R&D with agentic insights - Select Science
Revvity, Inc.(NYSE: RVTY) added to Russell 2500 Index - marketscreener.com
Revvity sets its post-Pandemic health strategy, shares on the NYSE in a diversified diagnostics peer - AD HOC NEWS
Revvity opens the weekend with strategy focus, shares on NYSE radar - AD HOC NEWS
Enterprise value to revenue forward of Revvity, Inc. – NYSE:RVTY - TradingView
REVVITY INC : BERNSTEIN RESUMES COVERAGE WITH MARKET-PERFORM RATING; PRICE TARGET $115 - Moomoo
Price to sales forward of Revvity, Inc. – NYSE:RVTY - TradingView
Revvity (RVTY) Coverage Initiated by Bernstein with $115 Target - GuruFocus
Price to earnings forward of Revvity, Inc. – NYSE:RVTY - TradingView
RVTY Reinstated by Bernstein -- Market Perform Rating Announced - GuruFocus
Bernstein Maintains Revvity(RVTY.US) With Hold Rating, Maintains Target Price $115 - Moomoo
Bernstein SocGen resumes Revvity stock coverage with Market Perform - Investing.com UK
RVTY Forecast — Price Target — Prediction for 2027 - TradingView
Revvity Inc. stock outperforms competitors on strong trading day - MSN
Revvity, Inc. Actuals & Estimates (NYSE:RVTY) - TradingView
Bernstein SocGen resumes Revvity stock coverage with Market Perform By Investing.com - Investing.com India
Revvity launches Signals AI to advance scientific R&D workflows - MSN
PKN Forecast — Price Target — Prediction for 2027 - TradingView
Revvity, Inc. Actuals & Estimates (DUS:PKN) - TradingView
Revvity plans second quarter earnings release, shares on NASDAQ in a crowded diagnostics peer group - AD HOC NEWS
Revvity Inc (RVTY) Shares Surge 7.5% -- What GF Score of 75 Tells Investors - GuruFocus
Revvity, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.0357143 Sh - TradingView
Revvity Rises as Investors Weigh New AI Launch and Earlier Q1 Strength - Moomoo
Revvity Jumps 6.8% Amid Sector-Wide Rally - AlphaStreet
Global Laboratory Equipment Services Market Size/Share Worth USD 62.83 Billion by 2035 at a 8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
How Revvity’s New Signals AI-Powered R&D Platform (RVTY) Has Changed Its Investment Story - simplywall.st
Barclays Maintains Revvity(RVTY.US) With Hold Rating, Maintains Target Price $105 - Moomoo
Revvity edges higher with a clear analyst consensus, shares backed by Buy ratings - AD HOC NEWS
Revvity Launches Signals AI to Advance Scientific R&D Workflows - Zacks Investment Research
Revvity Enhances AI Features in Signals Software (RVTY) - GuruFocus
Revvity focuses on biologics software strategy, shares trade quietly on the NYSE - AD HOC NEWS
Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D - 01net
Revvity Expands Signals One Platform With New AI Capabilities for Scientific R&D - citybiz
Revvity Inc. (RVTY) Slides Slightly Amid Cautious Trading, Holds Above Key SupportIV Rank - dars.gov.et
Revvity Inc. Stockbackground snapshot on diagnostics and life science tools - AD HOC NEWS
Revvity StockWeekly review and sector context - AD HOC NEWS
Is Revvity Stock Underperforming the Nasdaq? - Barchart
Why Revvity’s Signals Image Artist software is becoming a quiet lab workhorse - AD HOC NEWS
Revvity Inc (RVTY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Revvity Inc (RVTY) Institutional Confidence - TradingKey
Revvity Inc (RVTY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):